ロード中...
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8007566/ https://ncbi.nlm.nih.gov/pubmed/33782470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-86482-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|